Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

University of Sao Paulo

Status and phase: Completed; Phase 2

Conditions: Age Related Macular Degeneration; Diabetic Retinopathy

Treatments: Drug: Brimonidine tartarate; Procedure: Anterior chamber paracentesis; Drug: Acetazolamide

Study type: Interventional

Funder types: Other

Identifiers

NCT00864838

4429/2008

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.

Enrollment: 56 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of age related macular disease or diabetic retinopathy
• Able and willing to provide informed consent

Exclusion criteria

• History of ocular hypertension or glaucoma
• High Myopes (> 6 spherical diopters)
• High Hyperopes (> 4 spherical diopters)
• Pulmonary disease
• Renal disease
• Known allergy to any component of the study drug
• Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

56 participants in 4 patient groups

1

No Intervention group

Description:

Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation

2

Experimental group

Description:

Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection

Treatment:

Drug: Acetazolamide

3

Experimental group

Description:

topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection

Treatment:

Drug: Brimonidine tartarate

4

Experimental group

Description:

anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab

Treatment:

Procedure: Anterior chamber paracentesis